These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 21211686

  • 21. [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].
    Kawamori R.
    Nihon Rinsho; 2010 Feb; 68(2):235-41. PubMed ID: 20158090
    [Abstract] [Full Text] [Related]

  • 22. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
    Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM, STRADIVARIUS Investigators.
    JAMA; 2008 Apr 02; 299(13):1547-60. PubMed ID: 18387931
    [Abstract] [Full Text] [Related]

  • 23. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    Perségol L, Duvillard L, Monier S, Brindisi MC, Bouillet B, Petit JM, Vergès B.
    J Clin Endocrinol Metab; 2014 Oct 02; 99(10):E2015-9. PubMed ID: 25137425
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.
    Kutoh E.
    Endocr Res; 2010 Oct 02; 35(3):118-27. PubMed ID: 20712426
    [Abstract] [Full Text] [Related]

  • 28. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.
    Kataoka Y, Shao M, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, Nicholls SJ.
    Eur J Prev Cardiol; 2013 Apr 02; 20(2):209-17. PubMed ID: 22345692
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes.
    Clark D, Nicholls SJ, St John J, Elshazly MB, Kapadia SR, Tuzcu EM, Nissen SE, Puri R.
    Eur Heart J; 2018 Jul 14; 39(27):2551-2558. PubMed ID: 29688308
    [Abstract] [Full Text] [Related]

  • 31. Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome.
    Rodés-Cabau J, Tardif JC, Cossette M, Bertrand OF, Ibrahim R, Larose E, Grégoire J, L'allier PL, Guertin MC.
    Am J Cardiol; 2009 Sep 15; 104(6):750-7. PubMed ID: 19733706
    [Abstract] [Full Text] [Related]

  • 32. Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound.
    Kataoka Y, Shao M, Wolski K, Uno K, Puri R, Murat Tuzcu E, Hazen SL, Nissen SE, Nicholls SJ.
    Atherosclerosis; 2014 Feb 15; 232(2):377-83. PubMed ID: 24468151
    [Abstract] [Full Text] [Related]

  • 33. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials.
    Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE.
    J Am Coll Cardiol; 2008 Jul 22; 52(4):255-62. PubMed ID: 18634979
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
    Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S, Ohkawa K, Ishizawa M, Yamaji H, Kawamura H, Kusachi S, Murakami T, Hina K, Ohe T.
    J Am Coll Cardiol; 2010 Mar 09; 55(10):976-82. PubMed ID: 20202514
    [Abstract] [Full Text] [Related]

  • 37. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 09; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 38. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Perez A, Provost JC, Haffner SM.
    JAMA; 2006 Dec 06; 296(21):2572-81. PubMed ID: 17101640
    [Abstract] [Full Text] [Related]

  • 39. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
    Qamar A, Khetarpal SA, Khera AV, Qasim A, Rader DJ, Reilly MP.
    Arterioscler Thromb Vasc Biol; 2015 Aug 06; 35(8):1880-8. PubMed ID: 26069232
    [Abstract] [Full Text] [Related]

  • 40. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
    Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP.
    Diabetes Care; 2004 Jan 06; 27(1):41-6. PubMed ID: 14693964
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.